Friday, 18 Aug 2017

You are here

MSK Ultrasound Now Standard for Rheumatology Training

In the United States, musculoskeletal ultrasound (MSUS) in rheumatology has grown significantly in the last few decades. Ten years ago, more than half of rheumatology fellows had training or exposure to MSUS. A current survey of training programs shows that 94% provide MSUS training.

A survey of 113 rheumatology fellowship program directors yielded a 96% response rate (108/113). MSUS is currently being taught in 94% of programs, with 41% having a formal MSUS curriculum.

Program size did not influence curriculum. Nearly all (95.3%) program directors favored a formal curriculum but two-thirds preferred it to be optional. Use of external courses, including a USSONAR course, was prevalent. There still exists a lack of time, funding and trained faculty, but MSUS is firmly rooted in the vast majority of rheumatology training program.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review – 18 August 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes new data on lupus survival, pediatric lupus guidelines from SHARE, room temperature storage of etanercept, over or under-testing by rheumatologists and failure of pain meds to treat pain.

The RheumNow Week in Review – 11 August 2017

The RheumNow Week in Review caps the week's news every Friday. Dr Jack Cush reviews the news, journal reports and important events from the past week in rheumatology.  This week's news highlights include new data on the incidence of arthritis, lag times in patient referral, criteria for referral and why/how weather change affects arthritis pain.

Criteria for Early Referrals from Primary Care

Early diagnosis and early intervention has been the mantra of all who manage musculoskeletal (MSK) diseases for decades. While the rules for referral may be clear to some, the lack of uniformity and promotion amongst primary care providers is less certain.

The RheumNow Week in Review – 4 August 2017

Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on RheumNow.com. 

The RheumNow Week in Review – 28 July 2017

Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com: